What Happens to Muscle When Semaglutide Drives Weight Loss

A retrospective observational study published this week in Obesity Facts tracked changes in body composition, muscle strength, and resting energy expenditure in adults with obesity treated with semaglutide over 12 months in routine clinical care. The question it addressed has become central to the GLP-1 conversation: when weight drops rapidly, what happens to lean tissue?

The study followed 83 patients at a single obesity treatment unit in Barcelona. Forty-four received a lifestyle education program plus subcutaneous semaglutide; 39 received the lifestyle program alone. All were adults with a BMI of 30 or above and no diabetes. Researchers measured body composition via bioelectrical impedance, handgrip strength with a dynamometer, and resting energy expenditure using indirect calorimetry at baseline and at 12 months.

The semaglutide group lost an average of 11.0 kg, compared to a non-significant change in the lifestyle-only group. Waist circumference fell by 7.0 cm. Fat mass and visceral fat indicators dropped.

Lean mass also decreased — skeletal muscle mass went from 29.9 kg to 28.7 kg, and fat-free mass from 53.8 kg to 52.7 kg. On its own, that reading would feed the concern that GLP-1–mediated weight loss comes at a cost to muscle.

But a second metric tells a different story. The researchers used a reference-based skeletal muscle index standardized deviation score (SMI-SDS), validated against MRI data, to assess whether the muscle that remained was structurally appropriate for the patient’s age and BMI. In the semaglutide group, the SMI-SDS improved significantly — a delta of 0.52 versus 0.09 in the lifestyle group — indicating that the lean tissue lost was disproportionately the excess relative to reference norms. In other words, the absolute numbers fell, but the quality-adjusted muscle profile got better.

Absolute handgrip strength stayed stable in both groups. Relative handgrip strength — strength adjusted for body weight — improved in the semaglutide group (p = 0.003), suggesting that functional capacity per kilogram rose even as total mass declined.

Resting energy expenditure dropped in both groups, and part of the decline exceeded what would be predicted from changes in fat mass, fat-free mass, age, and sex — a phenomenon known as adaptive thermogenesis. The magnitude was somewhat larger in the lifestyle group (approximately 373 kcal/day below predicted) than in the semaglutide group (approximately 210 kcal/day below predicted), but the between-group difference was not statistically significant.

The study carries the usual limitations of a single-center retrospective design: 83 patients, no randomization, and groups assigned by clinical decision rather than protocol. Body composition was measured by bioelectrical impedance rather than DXA. Still, it adds real-world data to a question that has mostly been discussed in the abstract: whether the lean tissue lost during GLP-1 therapy is the kind worth keeping.

The evidence here suggests that semaglutide reduces absolute lean mass while also improving muscle quality relative to reference standards, and that handgrip strength — a proxy for functional muscle — is at least preserved. The question of long-term metabolic adaptation from the drop in resting energy expenditure remains open. For those looking to explore the broader reference data on GLP-1 receptor agonists, the Research Protocols archive maintains indexed protocol records.